

Claims 9 and 13 have been amended to clarify the antecedent basis of certain limitations. No prohibitive new matter has been added.

Claim 9 has been amended to make inherent quality of mixed components explicit in the claim. This amendment is supported by the claim as filed, and also by the disclosure found at page 18, lines 25-28 and page 19, lines 16-17. No prohibited new matter is added.

Claim 9 has also been amended to clarify that the selected target cell or tissue must express a mutant EGFR gene. Disclosure of mutant EGFR gene expression is found throughout the instant application, and particularly at page 8, lines 26-29. Thus no prohibited new matter has been added.

Claims 8, 12 and 16 have been amended to more clearly define the class of contemplated “derivatives.” Supporting disclosure is found at page 26, lines 12-16. No prohibited new matter is added.

III. Withdrawn Objections and or Rejections.

Applicants acknowledge with appreciation that the previous rejection under 35 U.S.C. section 112, paragraph 2, relating to the use of the phrase “relatively selective” in claims 7, 11 and 15 has not been maintained.

IV. Rejections under 35 U.S.C. section 112, paragraph 2 (indefiniteness)

A. Use of the term “Derivatives.”

Claims 8, 12 and 16 have been rejected as indefinite in their limitation of the class of contemplated tyrosine kinase inhibitors to “Tyrphostin AG1478 and its derivatives.” In particular, it has been stated that the phrase “its derivatives” has no particular art-recognized meaning, and has not been adequately defined in the specification. *See* Office Action dated February 17, 2000, pp. 2-3. During the November 20, 2000 interview, Applicants were further asked to consider the outer boundaries of the term “derivatives,” and specifically what is

excluded by the term. Applicants have considered the Examiner's comments and respectfully submit that the term "derivative" in conjunction with the foregoing amendments places claims 8, 12 and 16 in condition for allowance.

Applicants begin by noting that the limitations of a claim cannot be, and are not required to be, defined with absolute numerical precision. The limitations of a claim need only be as "precise as the subject matter permits." *Rosemount, Inc. v. Beckman Instruments, Inc.*, 727 F.2d 1540, 1547 (Fed. Cir. 1984) (approving of the limitation "close proximity"). Consequently, terms such as "substantially equal" or "closely approximate" without more, have all been held to meet the definiteness requirements of 35 U.S.C. 112, second paragraph. *See Andrew Corporation v. Gabriel Electronics, Inc.*, 847 F.2d 819, 822 (Fed. Cir. 1988). Applicants respectfully submit that the phrase "its derivatives," like the preceding terms, is as precise as the art admitted at the time of filing. Applicants also submit that the class of AG1478 derivatives is fairly constrained. Even were the claimed class broad, however, Applicants further note that breadth cannot be equated with indefiniteness. *See* MPEP § 2173.04.

Applicants also respectfully draw attention to the fact that the term "derivative" is commonly used in the art when describing various tyrphostins. *See e.g.*, Levitzki *et al.* "Tyrosine Kinase Inhibition; an Approach to Drug Development," *Science* (1995) Vol. 267, pp. 1782-1788 (filed herewith). As one can see from Table 2 of Levitzki *et al.*, tyrphostin compounds that are made from a particular precursor are considered to be a "derivative" of that precursor. *See* Levitzki *et al.*, Table 2 (identifying several classes of tyrphostin derivatives of dihydroxy- or dimethoxy-benzylidenemalononitrile ("BMN") compounds). For example, the "quinoline derivatives" are tyrphostins that are made via a cyclizing reaction or condensation of the "CN" group found in the precursor BMN compound. *Id.* (Structure M). Other derivatives involve the addition of particular side chains or groups. *Id.* (Structure N, showing addition of phosphate group).

A “derivative” is simply that; a compound made or derived from a precursor compound, whether by, for example, substitution, addition or cyclic condensation. Applicants further note that the foregoing art-recognized meaning of “derivative” is absolutely consistent with their use of the term in the present application. At page 7, line 27 to page 8, line 3, Applicants refer to 7-hydroxystaurosporine as a derivative of staurosporine. The obvious difference between the two compounds residing in the addition of a hydroxy group to make the “derivative.”

More importantly, not all derivatives of AG1478 are encompassed by the claims. First and foremost, the recited derivative must be a tyrosine kinase inhibitor with the effects on apoptosis as particularly set forth in claims 1, 9 and 13. Furthermore, the class of derivatives is narrowly confined to those derivatives with a lower toxicity, better selectivity for Δ EGFR or greater bioavailability than AG1478. Thus, the claims are tailored to exclude non-functional or non-improving derivatives of AG1478.

Applicants respectfully submit that they have demonstrated that the term “derivatives” is an art-recognized description of the contemplated claim scope. Applied to the claims at issue, derivatives of AG1478 would be understood to be compounds that can be synthesized from AG1478 and which have the limitations as recited both in claims 1, 9, 13, and as further limited by the requested amendments. In light of the foregoing, Applicants respectfully request that the rejection for indefiniteness may be withdrawn.

B. Lack of Antecedent Basis.

Claims 9 and 13 have been rejected under section 112, paragraph 2, based on lack of antecedent basis regarding the limitations “the resistance,” “the induction” and “the increased rate.” Applicants acknowledge with appreciation the Examiner’s suggestions regarding amendments to the claims. Applicants have adopted the proposed amendments to the claims in the interest of expediting allowance of the claims. Applicant’s respectfully submit that the rejection of claims 9 and 13 for lack of antecedent basis may be withdrawn.

C. Use of the Phrase “Target cell or tissue.”

Claims 9 and 13 have also been rejected under section 112, paragraph 2, as indefinite regarding the limitation “target cell or tissue.” The Examiner has helpfully proposed that the claims be amended to recite a target cell or tissue --of a mutant EGFR gene--.

In their previous response, Applicants noted that a “target cell or tissue” is one that has the recited resistance to apoptosis and “the resistance is mediated by a mutant EGFR.” *See, e.g.*, claim 9. Consequently, amendment of the claims should be unnecessary. It has been stated, however, that the “issue is not the nature of the resistance, but rather the nature of the ‘target cell or tissue.’” *See* Office Action dated February 14, 2000, page 4. To expedite allowance of the claims, Applicants have amended the claims to recite a “target cell or tissue expressing a mutant EGFR gene.” Applicants have slightly rephrased the Examiner’s proposed amendment to enhance the readability of claims. In light of the foregoing amendments to claims 9 and 13, Applicants respectfully request that the rejection under section 112, paragraph 2, regarding the limitation “target cell or tissue” be withdrawn.

V. 35 U.S.C. section 103

Claims 1-16 have been rejected as unpatentable under 35 U.S.C. § 103 over Han *et al.* in light of Reed. Applicants respectfully submit that the rejection may be withdrawn because the art fails to teach the invention in all of its properties, including unexpected properties, and also because of the contrary teachings of the art, which would direct one of ordinary skill to do the opposite of what Applicants have done.

A. The Unexpected, Synergistic Properties of the Invention are not Suggested by the Art.

Evidence of unexpected and beneficial properties is evidence of non-obviousness. MPEP §716.02(a). Moreover, in determining obviousness, the invention as a whole must be considered, including inherent properties. MPEP § 2141.02. Applicants respectfully submit that the present

invention possesses unexpected benefits that are wholly absent from the teachings of the cited art.

It has been acknowledged that the primary reference, Han *et al.*, does not disclose that a “tyrosine kinase inhibitor such as tyrphostin AG1478 should be administered together with a therapy which is effective to induce apoptosis or increase the rate of apoptosis.” *See* Office Action dated June 23, 1999, p. 5. The Examiner has also stated, however, that “a combination of old ingredients where the results are merely additive is not patentable and that no unexpected results have been shown by the Applicants.” *Id.* at 7-8.

Applicants respectfully submit that the results obtained by the use of a tyrosine kinase inhibitor with the recited agent are not “additive” and are not suggested by the prior art. Specifically, Figure 6B of the pending application shows that apoptosis level is dramatically and synergistically increased when the inhibitor and agent are combined. For example, the addition of 10 μ M AG1478 increases the apoptotic response (%TUNEL positive cells) of Δ EGFR expressing cells treated with cisplatin from under 10% to over 15%, while having only negligible effect when used in the absence of cisplatin. *See also*, Application at page 25, line 28 to page 26, line 9 (discussing synergistic properties of combination therapy). Clearly, these results are not “additive.”

Because the claimed invention possesses unexpected and beneficial synergistic properties – properties that the art fails to teach or even suggest – Applicants respectfully request that the rejection for obviousness be withdrawn.

B. The Art Teaches Away from Applicants Invention.

The non-obviousness of Applicants’ invention is further supported by the contrary teachings of the art. MPEP §2145.X.D. Specifically U.S. Patent No. 5,597,798 to Howell *et al.*, discloses that the administration of EGF increases sensitivity to agents such as cisplatin. EGF is commonly known to increase the tyrosine kinase activity of the EGF receptor (EGFR). Yet, Applicants achieve greater cell sensitivity to agents not by increasing kinase activity, but by

but see
Gulli p. 123

reducing it with inhibitors. Had Applicants or the artisan of ordinary skill followed the teachings of Howell *et al.*, they would never have discovered that tyrosine kinase inhibitors can play a critical role in combination therapy.

but see
Levitalki
p. 913

Because the art taught to do the opposite of what Applicants have done, Applicants respectfully request that the rejection for obviousness be withdrawn.

VI. Duplicative Claims.

Claims 13-16 have been objected to as duplicative of Claims 9-12. Applicants respectfully submit that the claims as amended are not duplicative.

Claims of differing scope may not be rejected as duplicative. MPEP § 706.03(k). Although claims 9-12 and 13-16 recite the same component agents and inhibitors, a distinction between the claims resides in the relationship of these components. Specifically, claims 9-12 are drawn to single compositions in which the recited component agent and inhibitor are found together. Page 18, lines 25-28, for example, refers to compositions of the invention which contain a tyrosine kinase inhibitor, a chemotherapeutic agent, and which may (but need not) contain “suitable pharmaceutically acceptable carriers . . .” This indicates compositions in which the two components are inherently mixed. *See also*, page 19, lines 16-17 (referring to “two-component compositions of the invention . . .”) The contemplated invention is broader than these claimed compositions, however.

As disclosed in the application, agents and inhibitors of the invention may be used for “combination therapy,” which may involve independent or separate administration of the agent and inhibitor. *See* Application at page 16, line 24 to page 17, line 3; page 19, lines 16-22. As such, the agents and inhibitors of the invention may be marketed or prepared as a single composition or as separate components. To address this situation, Applicants have drafted claims 13-16 as “kits” to encompass situations where the agents and inhibitor are supplied together as separate components. Applicants further submit that the term “kit” is readily

understood by the skilled artisan to encompass the supply of the recited agents and inhibitors as unmixed components; while it is generally understood that the term "composition" does not.

Applicants respectfully submit that claims 9-12 and 13-16 differ in scope as written. However, in the interest of expediting allowance of the claims, Applicants have amended Claim 9 to underscore that the recited components are mixed. As such, Applicants submit that as amended claims 9 and 13 clearly differ in scope and are not duplicative in nature. Applicants respectfully request, therefore, that the objection for duplicative claims be withdrawn.

CONCLUSION

The foregoing amendments are being made to place the application in condition for allowance. Applicants respectfully request reconsideration and the timely allowance of the pending claims. A favorable action is awaited.

The Examiner is thanked for her insightful and helpful suggestions. Should the Examiner find that an interview is required to further prosecution of this application, she is invited to telephone the undersigned at her convenience.

Except for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17, which may be required, to our Deposit Account No. 50-0310. If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

Dated: December 18, 2000

Customer No. 009629
MORGAN, LEWIS & BOCKIUS LLP
1800 M Street, N.W.
Washington, D.C. 20036-5869
(202) 467-7000

By:



Thomas F. Poché
Reg. No. 45,017

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

CURRENT
AWARENESS
TITLE

A 5205

Univ. of Minn.
Bio-Medical
Library

3 28 95

#BXNCCNG ***** CAR-RT SORT ** C055
#000018948729#AS 12/15/95 N 1295 46
UNIVERSITY MINNESOTA
BIOMEDICAL LAB 325A DIEHL
505 ESSEX ST
MINNEAPOLIS MN 55455-0350

Tyrosine Kinase Inhibition: An Approach to Drug Development

Alexander Levitzki* and Aviv Gazit

Protein tyrosine kinases (PTKs) regulate cell proliferation, cell differentiation, and signaling processes in the cells of the immune system. Uncontrolled signaling from receptor tyrosine kinases and intracellular tyrosine kinases can lead to inflammatory responses and to diseases such as cancer, atherosclerosis, and psoriasis. Thus, inhibitors that block the activity of tyrosine kinases and the signaling pathways they activate may provide a useful basis for drug development. This article summarizes recent progress in the development of PTK inhibitors and demonstrates their potential use in the treatment of disease.

Phosphorylation of proteins on tyrosine constitutes less than 0.01% of the total intracellular phosphorylation. Phosphorylation on tyrosine residues occurs almost exclusively in metazoa and is absent from unicellular eukaryotes, with the exception of regulators of cell cycle kinases and members of the mitogen-activated protein (MAP) kinase family, in which simultaneous phosphorylation of tyrosine and threonine is catalyzed by a specialized kinase that differs from classical PTKs. Tyrosine phosphorylation may be the primary, or even the exclusive, indicator of signal transduction in multicellular organisms (1). The receptor tyrosine kinases (RTKs) participate in transmembrane signaling, whereas the intracellular tyrosine kinases take part in signal transduction within the cell, including signal transduction to the nucleus (2). Enhanced PTK activity resulting from tyrosine kinase overexpression can activate mutations or lead to persistent stimulation by autocrinally secreted growth factors, which in turn can lead to disease (3). Decreased function can also be harmful; for example, a decrease in the activity of the insulin RTK is the cause of various types of diabetes (4). Severe reduction of the B cell progenitor kinase leads to human X-linked agammaglobulinemia (5).

Enhanced activity of tyrosine kinases has been implicated in many cancers and other proliferative diseases, as well as in nonmalignant proliferative diseases such as atherosclerosis (6) and psoriasis (7) and in a large number of inflammatory responses such as septic shock (8, 9). Tyrosine kinases and the signaling pathways in which they participate have therefore been identified as potential targets for drug design. In the past decade, many laboratories embarked on projects aimed at generating compounds

that inhibit the activity of the signaling cascades triggered by tyrosine kinases (10). These signaling pathways can be intercepted at various steps, as shown in Fig. 1.

One possible approach to intercepting these pathways is to develop biological reagents that inhibit the binding of a growth factor to its receptor. This has been achieved in the case of the HER2-Neu RTK, which is overexpressed in ~30% of breast and ovary carcinomas (11). Antibodies to HER2 have been produced and are currently in phase II clinical trials. Another approach is to develop growth factor antagonists. This approach has not been success-

ful, although attempts to develop low molecular weight insulin mimics or growth factor antagonists have been quite intensive. However, the drug suramin stands out as an example of the potential of this approach. This compound, initially developed as an antitrypanosome agent (12), was found to inhibit tumor cells with good efficacy but is quite toxic. The main mechanism of action of suramin may involve inhibition of the binding of growth factors to their receptors (13). Suramin has been used for treatment of renal carcinoma (14) and prostate carcinoma (15) with notable efficacy. Attempts are under way to develop suramin analogs that inhibit binding of specific growth factors to their receptors.

The action of a receptor can also be nullified with a growth factor-toxin chimera. In this case, the toxin would be internalized by receptor-mediated endocytosis of the chimera, which would destroy the receptor-harboring cell (16). Another possible approach is to block the interaction of an activated RTK or intracellular tyrosine




Fig. 1. Points of interception of PTK signaling pathways. GF, growth factor; PI, phosphatidylinositol; PTP, protein tyrosine phosphatase.

The authors are in the Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University of Jerusalem, Jerusalem 91904, Israel.

*To whom correspondence should be addressed.

*NOTICE: THIS MATERIAL MAY BE PROTECTED BY COPYRIGHT LAW (TITLE 17 U.S. CODE)

Tyrosine Kinase Inhibition: An Approach to Drug Development

Alexander Levitzki* and Aviv Gazit

Protein tyrosine kinases (PTKs) regulate cell proliferation, cell differentiation, and signaling processes in the cells of the immune system. Uncontrolled signaling from receptor tyrosine kinases and intracellular tyrosine kinases can lead to inflammatory responses and to diseases such as cancer, atherosclerosis, and psoriasis. Thus, inhibitors that block the activity of tyrosine kinases and the signaling pathways they activate may provide a useful basis for drug development. This article summarizes recent progress in the development of PTK inhibitors and demonstrates their potential use in the treatment of disease.

Phosphorylation of proteins on tyrosine constitutes less than 0.01% of the total intracellular phosphorylation. Phosphorylation on tyrosine residues occurs almost exclusively in metazoa and is absent from unicellular eukaryotes, with the exception of regulators of cell cycle kinases and members of the mitogen-activated protein (MAP) kinase family, in which simultaneous phosphorylation of tyrosine and threonine is catalyzed by a specialized kinase that differs from classical PTKs. Tyrosine phosphorylation may be the primary, or even the exclusive, indicator of signal transduction in multicellular organisms (1). The receptor tyrosine kinases (RTKs) participate in transmembrane signaling, whereas the intracellular tyrosine kinases take part in signal transduction within the cell, including signal transduction to the nucleus (2). Enhanced PTK activity resulting from tyrosine kinase overexpression can activate mutations or lead to persistent stimulation by autocrinally secreted growth factors, which in turn can lead to disease (3). Decreased function can also be harmful; for example, a decrease in the activity of the insulin RTK is the cause of various types of diabetes (4). Severe reduction of the B cell progenitor kinase leads to human X-linked agammaglobulinemia (5).

Enhanced activity of tyrosine kinases has been implicated in many cancers and other proliferative diseases, as well as in nonmalignant proliferative diseases such as atherosclerosis (6) and psoriasis (7) and in a large number of inflammatory responses such as septic shock (8, 9). Tyrosine kinases and the signaling pathways in which they participate have therefore been identified as potential targets for drug design. In the past decade, many laboratories embarked on projects aimed at generating compounds

that inhibit the activity of the signaling cascades triggered by tyrosine kinases (10). These signaling pathways can be intercepted at various steps, as shown in Fig. 1.

One possible approach to intercepting these pathways is to develop biological reagents that inhibit the binding of a growth factor to its receptor. This has been achieved in the case of the HER2-Neu RTK, which is overexpressed in ~30% of breast and ovary carcinomas (11). Antibodies to HER2 have been produced and are currently in phase II clinical trials. Another approach is to develop growth factor antagonists. This approach has not been success-

ful, although attempts to develop low molecular weight insulin mimics or growth factor antagonists have been quite intensive. However, the drug suramin stands out as an example of the potential of this approach. This compound, initially developed as an antitrypanosome agent (12), was found to inhibit tumor cells with good efficacy but is quite toxic. The main mechanism of action of suramin may involve inhibition of the binding of growth factors to their receptors (13). Suramin has been used for treatment of renal carcinoma (14) and prostate carcinoma (15) with notable efficacy. Attempts are under way to develop suramin analogs that inhibit binding of specific growth factors to their receptors.

The action of a receptor can also be nullified with a growth factor-toxin chimera. In this case, the toxin would be internalized by receptor-mediated endocytosis of the chimera, which would destroy the receptor-harboring cell (16). Another possible approach is to block the interaction of an activated RTK or intracellular tyrosine




Fig. 1. Points of interception of PTK signaling pathways. GF, growth factor; PI, phosphatidylinositol; PTP, protein tyrosine phosphatase.

The authors are in the Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University of Jerusalem, Jerusalem 91904, Israel.

*To whom correspondence should be addressed.

kinase with its downstream targets. Because these interactions are often mediated by specific sequences at the Src homology 2 (SH2) domains on target proteins with the autophosphorylation sites on the RTK or the intracellular tyrosine kinase (17), it is possible to design or screen for inhibitory ligands. Certain adaptor molecules, such as Grb2, contain both SH2 and Src homology 3 (SH3) domains. The SH2 domain of Grb2 binds to an activated PTK, and its SH3 domain binds and recruits the Ras exchanger Sos to the membrane, which enables it to activate the Ras protein. Thus it is possible, in principle, to inhibit such interaction of SH3 domains and downstream effectors. Because the recognition sequences for SH2 domains (18) and for SH3 domains (19) are short, rapid progress in developing such antagonists is likely. Other targets are the interaction between Sos and Ras and between Ras and its effectors, such as Raf1. Farnesylation inhibitors that inhibit membrane localization of Ras have also been described (20). This review focuses on the development of inhibitors of PTK catalytic activity. This approach is productive because we know more about the mechanism of PTK activity (21) and the mode of inhibition of these inhibitors (22) than about any other step of the signaling cascade (Fig. 1).

Structure of PTK Inhibitors

Natural inhibitors. The compounds quercetin (23), genistein (24), lavendustin A (25), erbstatin (26), and herbimycin A (27), isolated from fungal extracts, are tyrosine kinase inhibitors that exhibit rather broad specificity in the micromolar range. These compounds have served as a starting point for the development of many types of synthetic PTK inhibitors. Quercetin itself inhibits many other kinases, but derivatives that inhibit PTKs but not serine-threonine kinases have been described (28). Genistein and lavendustin A are competitive inhibitors of adenosine triphosphate (ATP) in the kinase reaction and are noncompetitive with the protein substrate. These compounds are broad-spectrum tyrosine kinase inhibitors, probably because the ATP binding domain is highly conserved among tyrosine kinases (1). Lavendustin A analogs, in which the core pharmacophore has been trimmed, are competitive with both the protein substrate and ATP, thus acting as bisubstrate inhibitors (22). The natural inhibitor herbimycin A irreversibly blocks the intracellular tyrosine kinases Src (29) and Bcr-Abl (30), the epidermal growth factor receptor (EGFR) (31), and the RTK HER2-ErbB2 (32). This irreversible inhibition is prevented by sulfhydryl reagents. Studies of the mode of action of herbimycin A on

these proteins showed that labeling of proteins with herbimycin A targets them for degradation. The mechanism of action of herbimycin A differs from that of reversible inhibitors. It is likely that the kinases interact with the quinone moiety of herbimycin A, because simple benzoquinones have effects similar to those of herbimycin A (33). Erbstatin, a natural PTK inhibitor thought to be purely competitive with the protein substrate (26), was recently found to be competitive with both the substrate and ATP (22).

Mechanistic considerations in designing PTK inhibitors. The activation of receptors after growth factor binding is manifested by autophosphorylation (1), which exposes the active site to external substrates that in turn transmit the signal downstream. Autophosphorylation of receptors also creates specific phosphorylated tyrosine residues that serve as docking areas for downstream signal transducers. Thus, the efficacy of an inhibitor can be judged by its potency in inhibiting the initial autophosphorylation event or by its ability to inhibit the phosphorylation of downstream substrates (34). These efficacies may differ from each other; in the unphosphorylated state, the substrate binding domain may differ from its structure in the fully activated state. Indeed, some inhibitors are more effective in inhibiting autophosphorylation than they are in inhibiting the phosphorylation of exogenous substrates (35). In general, inhibitors would be expected to be less effective in inhibiting the autophosphorylation step, because in the autophosphorylation reaction the substrate concentration is high as a consequence of the proximity effect (34).

The potency of natural PTK inhibitors deserves further study with respect to PTK autophosphorylation and to the activity of the PTK toward exogenous substrates. Detailed kinetic analyses of the mode of action of tyrosine kinase inhibitors may also reveal whether the PTK inhibitor is competitive (or partially competitive) with ATP, with the protein substrate, or with both as a bisubstrate inhibitor (22). Preferably, compounds to be examined should be competitive with the protein substrate and should be potent in inhibiting autophosphorylation of the tyrosine kinase. A highly potent PTK inhibitor of the autophosphorylation reaction is likely to be a more effective agent, because efficacious inhibition of autophosphorylation should lead to a complete shutoff of the signaling pathway. Indeed, PTK blockers that have been found to inhibit autophosphorylation of EGFR also inhibit phosphorylation and activation of phospholipase C- γ (PLC- γ) as well as EGF-dependent cell proliferation (34-37). Other criteria for successful inhibitors are selectivity, cell permeability, bioavailability, ap-

propriate pharmacokinetic properties, and nontoxicity.

Synthetic inhibitors. The naturally occurring inhibitors serve as excellent models for the design of synthetic inhibitors. Selective derivatives of quercetin have been described (28). Erbstatin is a promising natural compound that inhibits EGFR and Src (26). The benzylidene moiety of erbstatin and other arylidene compounds (38) were incorporated into a class of PTK blockers defined as tyrphostins (to indicate tyrosine phosphorylation inhibitors) (34, 35). A few similar compounds were prepared independently (39). Compounds belonging to the dihydroxy- and dimethoxybenzylidene malononitrile (BMN) class of PTK inhibitors have good efficacy in vivo (40). The recently discovered natural 3,4-dihydroxybenzene PTK inhibitor was found to be active in vitro (41). Lavendustin A was also found to repay further investigation, and some derivatives have been found to be more selective than the parent compound (22, 31, 42). Some lavendustin A analogs can discriminate between the EGFR kinase and p56^{Lck} in vitro (43). Also, AG814, an analog of lavendustin A, is competitive in the EGFR kinase reaction with both the protein substrate and ATP (22). In contrast, the bulky parent compound lavendustin A (22) is strictly an ATP competitor (25). Moreover, the smaller molecular size of lavendustin analogs such as AG957 (22, 31, 42) allows them to permeate cells, whereas lavendustin A does not. Quinazolines such as AG1478 (Fig. 2T) are highly selective for EGFR (44). The amount of quinazoline required to inhibit enzyme activity by 50% (IC₅₀) is in the nanomolar range (44), whereas micromolar concentrations are required for inhibition of the HER2-ErbB2 kinase and much higher concentrations are required for inhibition of the platelet-derived growth factor receptor (PDGFR) in vitro or in intact cells (45). The 4,5-dianilinophthalimides (Fig. 2S) selectively inhibit EGFR and HER2-ErbB2 (46), and quinoxalines are selective for PDGFR (47). Both quinazolines (44) and 3,4-dianilinophthalimide (46) are competitive with ATP, but their exact mode of competition with respect to the protein substrate is not known.

Thiazolidinediones constitute yet another family of PTK inhibitors that inhibit EGFR and Src in vitro and in intact cells in the low micromolar range (48). Although many of the PTK inhibitors appear to be pure competitors with the protein substrate or pure competitors with ATP, a more thorough kinetic analysis reveals that they are actually bisubstrate inhibitors that compete with both the protein substrate and ATP (22). It therefore appears that selectivity can be obtained by generating inhibitors

that compete in any of these three ways. Quinazolines, for example, represent a class of competitive inhibitors with respect to ATP that are highly selective for EGFR (44). In a number of other instances, good selectivity for protein kinase inhibitors has also been demonstrated; a detailed analysis of Bcr-Abl shows that (i) this PTK phosphorylates tyrosine-containing polymers different from those phosphorylated by the EGFR kinase, and (ii) the two kinases are sensitive to different classes of inhibitors. Moreover, c-Abl and Bcr-Abl differ from each other in their substrate specificity (31, 42). Quinoxalines (Fig. 2Q) are selective for PDGFR and do not inhibit Flk1-KDR or Src (47).

In some cases, PTK inhibitors that are potent on isolated PTKs *in vitro* are ineffective in intact cells. For example, AG494 and AG825, which are, respectively, selec-

tive for EGFR and HER2-Erb2 as isolated PTKs *in vitro*, are ineffective in inhibiting these receptors in intact cells unless the intracellular concentration of ATP is artificially reduced (49). Genistein, a pure competitive inhibitor of ATP (24), similarly inhibits only in the 50 to 100 μ M range in tissue culture systems and shows no efficacy *in vivo*. Kinetic analysis of many of the PTK blockers revealed that they are competitive with the substrate (22, 34, 43) and that they preferentially inhibit the EGFR kinase as compared with the insulin receptor kinase (34). The BMN PTK blockers inhibit not only EGFR kinase activity but also EGF-dependent cell proliferation in tissue culture (34, 37, 40). Furthermore, RG13022 and RG14620 inhibit the growth of human squamous cell carcinoma (which overexpresses EGFR) when implanted in

nude mice (40). RG13022 and RG14620 differ from the original arylbenzenemalononitrile in the absence of hydroxyl residues on the ring (40). The activity of the BMN tyrphostin AG490 in inhibiting the growth of human pre-B lymphoblastic leukemia cells *in vitro* and *in vivo* is correlated with its ability to inhibit tyrosine phosphorylation by the non-Src intracellular tyrosine kinase JAK-2 (50). Similarly, the BMN tyrphostin AG17, which is effective in inhibiting rabbit vascular smooth muscle cell proliferation *in vitro* (51), also inhibits restenosis in the rat carotid model (52).

Cells in tissue culture and in experimental animals tolerate relatively high doses of some tyrphostins, such as AG213 (RG50864), AG126, RG13022, RG14620, and AG555 (40, 52, 53). The benzene ring of the BMN compounds has been replaced by other aryl groups such as indole (30, 38), quinoline (54), and isoquinoline (55). Isoquinolines, which can be viewed as cyclic BMNs (Fig. 2O), selectively inhibit EGFR rather than p56^{Lck} *in vitro* (55). It is becoming apparent that although many PTK inhibitors are more selective than genistein, lavendustin A, and herbimycin A, each group inhibits several tyrosine kinases. Thus, for example, tyrphostin AG213 (RG50864), which inhibits EGFR 800 times as potently as it inhibits the insulin receptor (34), also inhibits several tyrosine kinases such as Bcr-Abl *in vitro* (31, 42) and inhibits thrombin-induced activation of Src family kinases in intact platelets (56). RG13022, which effectively inhibits EGFR and the growth of EGFR-overexpressing tumors *in vivo* (40), also was found to inhibit the growth of breast cancer cell lines that depended on the insulin-like growth factor IGF-1 (57). Improving the selectivity of PTK blockers remains a continuing learning process.

Structure activity relationships of PTK inhibitors. The core structures of most of the known PTK inhibitors are shown in Fig. 2, and data on the selectivities of some of these inhibitors are shown in Table 1. Piceatannol (Fig. 2A) is a natural product with a stilbene nucleus inhibitor (58), whereas nitrostyrene derivatives (Fig. 2B) are inhibitors of EGFR (59). The common pharmacophore for these inhibitors is the phenolic styrene (Fig. 2C), which can be viewed as a "dehydrogenated" tyrosine mimic. This pharmacophore is also part of the flavone skeleton of quercetin (Fig. 2D) and of the isoflavone skeleton of genistein (Fig. 2E). The synthesis of small molecular inhibitors was initially based on the nucleus of tyrosine itself. In designing tyrphostins (10, 34), we aimed at compounds that are relatively easy to prepare and that are amenable to structure activity relationship modification. The Knoevenagel reaction (Fig.





Fig. 2. Representative pharmacophores in tyrosine kinase inhibitors. (A) Piceatannol; (B) dihydroxynitrostyrene; (C) phenolic alkoxytyrosene; (D) quercetin; (E) genistein; (F) the Knoevenagel reaction; (G) 3,4-dihydroxy-*cis*-cinnamonnitrile; (H) AG17; (I) AG825; (J) AG789; (K) AG765; (L) AG308; (M) quinoline derivatives; (N) naphthalene derivatives; (O) and (P) isoquinoline derivatives; (Q) AG1296 (quinoxaline); (R) AG1112; (S) dianilinophthalimide derivatives; and (T) AG1478 (quinazoline).

146) of hydroxybenzaldehydes with malononitrile or its derivatives yielded BMNs, a family of tyrphostins with the desired properties (10, 34, 35). The basic pharmacophore in tyrphostins is 3,4-dihydroxy-cis-alkenylmalononitrile (Fig. 2G). These "first-generation" tyrphostins (34, 35) (Fig. 2F), in which $R = \text{CN}, \text{CONH}_2, \text{CSNH}_2$, or



where $R_1 = \text{H}, \text{OH}$, or OCH_3 , inhibited EGFR in vitro in the 0.3 to 1.0 μM range, whereas the insulin receptor was inhibited only in the millimolar range (34, 35). In-AG213, the natural compound BE-23372M, a 3,4-dihydroxybenzylidene flavone, is a potent EGFR kinase inhibitor (41). By preparing conformationally restricted analogs like AG307 and AG308 (Fig. 2, K and L) we established that optimal inhibition requires a cis-3,4-dihydroxycatechol ring and requires the nitrile to be in a cis and coplanar orientation. When the double bond is removed, the hydroxyls are removed, or the catechol ring is substituted with a heteroaryl ring, the affinity toward EGFR is reduced (34, 35). Substitution in the 5-position of the ring, or in the β -position (with $R = \text{F}, \text{Br}, \text{I}, \text{NO}_2$, or *tert*-butyl), neither improves nor diminishes activity (35). Substitution of the 5-position with various alkyl, aryl groups (49) yielded a series of potent tyrphostins. One of them, AG825, with a benzothiazole side chain (Fig. 2I and Table 1), inhibits the HER2-ErbB2 receptor 100 times as potently as it inhibits the related EGFR in vitro, despite the similarity of these tyrosine kinases (49).

Several analogs exhibit good inhibitory selectivity in cell culture. For example, AG555 and its congeners inhibit the growth of normal and psoriatic keratinocytes (60) (Tables 1 and 2) and of tumor cell lines that overexpress EGFR (35). In farnesyl tyrphostins, in which two amide derivatives are linked by oligomethylene bridges of various lengths, inhibit EGFR in a broad range of $\text{IC}_{50} = 0.1$ to 1.0 μM (61). AG17 (Fig. 2H) is a potent but nonselective inhibitor of several tyrosine kinases. A conformational modification yields AG879 (Fig. 2J), which inhibits nerve growth factor (NGF)-dependent Trk tyrosine phosphorylation in neuroblastoma cells ($\text{IC}_{50} \sim 40 \mu\text{M}$) (62) and also inhibits HER2-ErbB2 kinase in a number of breast and ovarian cancer cell lines ($\text{IC}_{50} \sim 1 \mu\text{M}$) (63). Another family of tyromolecostins, derived from AG1112 (Fig. 2R and Table 1), inhibits Bcr-Abl in K562 cells and induces those cells to undergo terminal myeloid differentiation (30, 42).

The planar bicyclic structure of flavones, and the improved potency of rigid tyrphostins such as AG308 (Fig. 2L) compared

with the open-structure tyrphostins, suggest that rigid bicyclic analogs formed by incorporating the cyanostyryl radical into the ring (Fig. 2M) could yield good inhibitors. The naphthalene derivative with no nitrogen in the ring (Fig. 2N) inhibits autophosphorylation of the insulin receptor only at high concentrations ($\sim 200 \mu\text{M}$) (64). Quinolines are moderate EGFR blockers with no effect on the insulin receptor (54). An isoquinoline derivative (Fig. 2O) inhibits p56^{Lck} autophosphorylation ($\text{IC}_{50} \sim 0.5 \mu\text{M}$) and inhibits EGFR ($\text{IC}_{50} > 100 \mu\text{M}$). A close analog (Fig. 2P) exhibited the opposite selectivity ($\text{IC}_{50} = 3.1 \mu\text{M}$ for EGFR; $\text{IC}_{50} > 100 \mu\text{M}$ for p56^{Lck}) (55). AG1478, a quinazoline, represents yet another class of highly selective EGFR inhibitors (Table 1) (44). Quinoxalines such as AG1296 (Fig. 2Q and Table 1) selectively inhibit PDGFR at 0.3 μM in intact cells











(47) and do not inhibit EGFR, the vascular endothelial cell growth factor receptor (VEGFR), and c-Src (47).

Biological Activities of Tyrphostins

Because PTKs participate in various proliferative diseases, we and others have explored the activity of PTK inhibitors as antiproliferative agents. Table 2 lists a variety of diseases in which PTKs are implicated, the mechanisms of PTK involvement for these diseases, and the PTK inhibitors that were found to inhibit the biological effects of these tyrosine kinases. The following sections discuss the potential of these PTK inhibitors in drug development.

Cancer. Because PTKs participate in the establishment and progression of many cancers, PTK inhibitors have potential in the

Table 1. Selectivity of PTK inhibitors in vitro. InsR, insulin receptor; N, not determined.

Tyrphostin		PTKs and IC ₅₀ values (μM)					
		EGFR	HER2-Neu	PDGFR	Trk	p210 ^{Bcr-Abl}	InsR
AG18		35	N	25	>100	75	4000
AG82		3	N	N	>100	3.6	N
AG213		0.8	N	3	>100	6	640
AG494		0.7	42	6	N	75	>100
AG555		0.7	35	N	N	N	>100
AG825		19	0.35	40	N	75	>100
AG879		>500	1.0	>100	10	N	N
AG1112		18.5	N	N	N	0.8	N
AG1296		>100	>100	0.5	N	>50	N
AG1478		0.003	>100	>100	N	>50	N

development of antineoplastic agents. PTK inhibitors have been studied extensively in tissue culture systems of transformed cells and in vivo. Potent PTK inhibitors of the EGFR kinase arrest the growth of cells that overexpress EGFR (34–37, 40, 46) and inhibit tumors that overexpress EGFR. For example, tyrphostins RG13022 and RG14620 inhibit the growth of human squamous cell carcinoma implanted in nude mice (40). 4,5-Dianilinophthalimides inhibit the growth of cells from human tumors that overexpress EGFR or HER2-ErbB2 and exhibit good antitumor activity in mice in which these tumors are grown as xenografts. Quinazolines such as PD153035 and AG1478 (Fig. 2T) are highly selective for EGFR and inhibit the EGFR kinase in the nanomolar range (Table 1) (44). Quinoxalines such as AG1296 (Fig. 2Q) inhibit the kinase activity of PDGFR and reverse the transformation of Swiss 3T3 cells by the *sis* oncogene (47). Tyrphostins such as AG213 and AG82 reverse the transformation of chicken lens cells by *v-Src* as well as that of NIH 3T3 cells by the activated mutant *pp^{60Src-F527}* (65). This reversal of transformation correlates with the inhibition of tyrosine phosphorylation of intracel-

lular substrates. Tyrphostin AG17 inhibits human pancreatic cancer cell lines (66), and AG1112 (Table 1) inhibits the phosphorylation of Bcr-Abl and of a few intracellular protein substrates in correlation with its potency to induce erythroid differentiation of K562 cells (30).

These results suggest that tyrphostins might be used to purge leukemic cells in patients with chronic myelogenous leukemia (CML) and might prolong the survival of patients at the chronic stage by eliminating cells that harbor the Philadelphia chromosome. Tyrphostin AG568 induces erythroid differentiation of mouse erythroleukemic cells in correlation with its inhibition of tyrosine phosphorylation of at least one protein (67). The selective inhibition of the proliferation of human pre-B acute lymphoblastic leukemia (ALL) cells by AG490 is in excellent correlation with its inhibition of intracellular tyrosine kinases. AG490 also has been shown to have excellent efficacy in vivo; its use resulted in a total cure of established ALL in mice with SCID (severe combined immunodeficiency disease) (50).

Restenosis. Tyrphostins that inhibit PDGFR have potential in the development

of drugs that inhibit restenosis, because PDGF and its receptor contribute to the formation of the atherosclerotic plaque (6). Because basic fibroblast growth factor (bFGF) and cytokines also take part in the formation of the atherosclerotic plaque, relatively broad-spectrum PTK inhibitors may be useful. Indeed, AG213 (RG50864) and AG18 inhibit the effect of the proliferative signals of both bFGF (68) and PDGF on rabbit vascular smooth muscle cells (51) and human bone marrow fibroblasts (38) and also inhibit thrombin-induced platelet aggregation (56). Thus, the therapeutic synthesis might include tyrphostins with a relatively broad spectrum that inhibit PDGFR, fibroblast growth factor receptor (FGFR), and nonreceptor PTKs that are activated during formation of the atherosclerotic plaque (6). Plaque formation is accompanied by an inflammatory component that is also mediated by intracellular tyrosine kinases, whose activities could be inhibited. It has been shown that tyrphostins effectively inhibit the activation of B cells (69), T cells (70), macrophages (71), neutrophils, mast cells, basophiles, and monocytes (72). Therefore, broad-specificity tyrphostins may be especially well suited for treating restenosis. Indeed, the nonselective tyrphostin AG17 (RG50872), which is effective as an antiproliferative agent on rabbit smooth muscle vascular cells grown in vitro (51), seems to fit this purpose. When restenosis is induced in the rat carotid artery and AG17 is applied from an engrafted polymer mantle encompassing the artery, the process of the disease is inhibited by about 70% (52).

Psoriasis and other skin conditions. Psoriatic lesions are typified by a few molecular indicators that strongly implicate the hyperactivity of PTKs. These include amplification of the gene for transforming growth factor- α (TGF- α) or for amphiregulin, or both, which leads to the persistent activation of EGFR on the psoriatic keratinocyte (7); the involvement of interleukin-6 (IL-6) (73) as the result of activation of cellular tyrosine kinases (74); and the involvement of IGF-I (75). We therefore examined the effect of tyrphostins on the growth of normal and psoriatic keratinocytes (60). Tyrphostins AG555 and AG18 arrest the growth of these cells without adverse cytotoxic effects. Because psoriasis affects up to 3% of the population, many people will benefit if compounds such as AG555 can be developed into effective antipsoriatic ointments. Such an approach can, in principle, be extended to other skin conditions such as Kaposi's sarcoma and papilloma, in which a number of PTKs have been implicated (76).

Sepsis and other inflammatory conditions. Lipopolysaccharide (LPS) is a Gram-nega-

Table 2. Selected diseases, the PTKs that are implicated in their progress, and tyrphostins (with reference numbers) that act as PTK inhibitors and have potential for drug development.

Disease	PTK implicated	Mechanism of PTK involvement	Tyrphostin
Certain cancers (squamous cell carcinoma)	EGFR	Amplification of the gene and overexpression of EGFR	RG13022 (40) AG1478 (44) 3,4-dianilinophthalimide (46)
Psoriasis	EGFR	Overexpression of the amphiregulin or TGF- α gene, or both, leading to persistent autocrine stimulation of EGFR	AG213 AG555 (60)
Mammary and ovary carcinomas	HER2-Neu	Gene amplification and overexpression of the HER2 protein	AG825 (49) AG1377 (61) AG879 (61)
Atherosclerosis, restenosis, pulmonary fibrosis	PDGFR	Stimulation of PDGFR by pathological release of PDGF (restenosis)	AG1295 (47) AG1296 (47)
Gliomas, glioblastomas	PDGFR	Amplification of PDGFR; coexpression of PDGF and PDGFR in the tumor	AG17 (51, 52) AG370 (51)
CML	p210 ^{Bcr-Abl} and p185 ^{Bcr-Abl}	Chromosome rearrangement that results in fusion of Bcr and p140c-Abl, leading to enhanced kinase activity	AG1112 (30, 31) AG957 (30, 31)
ALL	JAK-2	Enhanced tyrosine phosphorylation of intracellular proteins	AG490 (50)
Sepsis and other inflammatory conditions	LPS, TNF- α dependent phosphorylation on tyrosines	Probably enhanced activity of cytoplasmic PTKs from the Src family	AG126 (53) AG556 (53)

time bacterial endotoxin that causes the development of sepsis (septic shock) (77). This condition afflicts about 400,000 patients annually in the United States alone, and of the 200,000 hospitalized, 30 to 50% die (77). LPS induces tyrosine phosphorylation in target cells (8, 78); it also activates macrophages, inducing them to produce tumor necrosis factor α (TNF- α) and IL-1, which are important mediators of sepsis and of other inflammatory responses such as rheumatoid arthritis (79). TNF- α and IL-1 cause many of the symptoms of sepsis (80), and, like LPS, they induce tyrosine phosphorylation in target cells (81). Tyrphostins may therefore offer a double block by inhibiting LPS-induced TNF- α production as well as the action of TNF- α . Tyrphostins such as AG126 offer complete protection when injected into mice 2 hours before a lethal dose of LPS, and partial protection when injected at the same time as LPS (53). More potent tyrphostins such as AG556 offer nearly complete protection even when injected 2 hours after LPS. The protective tyrphostins inhibit LPS-induced TNF- α production, tyrosine phosphorylation of mitogen-activated protein kinase (MAPK), and production of NO in mouse macrophages (53). Inhibition of LPS-induced tyrosine phosphorylation and NO production also was reported for tyrphostin AG82, herbimycin A, and genistein (71, 82). These successes with tyrphostins in model systems for sepsis suggest that they may be useful in the management of other inflammatory diseases, such as rheumatoid arthritis, in which TNF- α is an important mediator (83).

Tyrosine kinase inhibitors in combination with other drugs. Because tyrphostins and other PTK inhibitors exhibit different selectivities, various combinations of these compounds might be useful. In most of the conditions described above, a number of tyrosine kinases are involved. Thus, an inhibitor with broad specificity or a combination of PTK inhibitors may be most effective. Tyrphostins also synergize with antibodies to EGFR to inhibit the growth of squamous cell carcinoma in vivo (40) and with cis-platin to block the growth of human cancer cells that overexpress HER2-ErbB2 (84). Another opportunity to be explored is the use of the antiestrogen ICI182,780 (85), in combination with tyrosine kinase inhibitors and cytotoxic drugs, to treat breast and ovarian cancers.

Conclusion

Approaches to drug design have become refocused in response to our rapidly emerging understanding of the role of signaling pathways in health and disease. Identification of receptors, enzymes, and adaptor proteins that mediate proliferative metabolic and inflam-

matory signals provide targets for drug design. In this review we have examined PTK inhibitors as potential drugs for a variety of disease states. The recent publication of the structure of the insulin receptor kinase domain (86) and its extensive homology to other PTKs will probably enhance the rational design of other PTK blockers. The reported success of tyrosine kinase inhibitors and inhibitors of other signaling molecules (87) suggests that such agents may be useful in the treatment of disease.

REFERENCES AND NOTES

1. A. Ullrich and J. Schlessinger, *Cell* **61**, 203 (1990).
2. X. Lia and T. Pawson, *Recent Prog. Horm. Res.* **49**, 149 (1994).
3. J. M. Bishop, *Science* **235**, 305 (1987).
4. D. Accili et al., *J. Endocrinol. Invest.* **15**, 857 (1992); S. I. Taylor, *Diabetes* **41**, 1473 (1992).
5. S. Tuskada et al., *Cell* **72**, 279 (1993).
6. R. Ross, *Lancet* **i**, 1179 (1989); *Nature* **362**, 801 (1993).
7. J. T. Elder et al., *Science* **243**, 811 (1989); P. W. Cook et al., *Cancer Res.* **52**, 3224 (1992); K. Hashimoto and K. Yoshikawa, *J. Dermatol. (Tokyo)* **19**, 648 (1992).
8. S. L. Weinstein, M. R. Gold, A. L. DeFranco, *Proc. Natl. Acad. Sci. U.S.A.* **88**, 4148 (1991).
9. Z. Dong et al., *J. Exp. Med.* **177**, 1071 (1993).
10. A. Levitzki, *FASEB J.* **6**, 3275 (1992); T. R. Burke Jr., *Drugs Future* **17**, 17 (1992).
11. D. J. Slamon et al., *Science* **244**, 707 (1989); S. S. Bacus et al., *Cancer Res.* **52**, 2580 (1992).
12. F. Hawkin, *Adv. Pharmacol. Chemother.* **15**, 289 (1978).
13. C. Betsholtz et al., *Proc. Natl. Acad. Sci. U.S.A.* **83**, 6440 (1986).
14. R. J. Motzer et al., *Cancer Res.* **52**, 5775 (1992).
15. B. L. Rappoport et al., *Anal. Oncol.* **4**, 567 (1993); C. Myers et al., *J. Clin. Oncol.* **10**, 881 (1992).
16. I. Pastan and D. FitzGerald, *Ann. N.Y. Acad. Sci.* **685**, 740 (1993).
17. T. Pawson et al., *Biochim. Biophys. Acta* **1155**, 239 (1993).
18. G. Waksman et al., *Cell* **72**, 773 (1993).
19. M. E. Noble et al., *EMBO J.* **12**, 2617 (1993); G. W. Bocker et al., *Cell* **73**, 813 (1993); D. Kohda et al., *ibid.* **72**, 953 (1993); R. Ren et al., *Science* **259**, 1157 (1993).
20. G. L. James et al., *Science* **260**, 1937 (1993); N. E. Kohl et al., *ibid.*, p. 1934.
21. I. Posner, M. Engel, A. Levitzki, *J. Biol. Chem.* **267**, 20638 (1992).
22. I. Posner, M. Engel, A. Gazit, A. Levitzki, *Mol. Pharmacol.* **45**, 673 (1994).
23. Y. Graziani et al., *Biochim. Biophys. Acta* **714**, 415 (1981); Y. Graziani, E. Erickson, R. L. Erickson, *Eur. J. Biochem.* **135**, 583 (1983).
24. T. Akyama et al., *J. Biol. Chem.* **262**, 5592 (1987).
25. T. Onoda et al., *J. Nat. Prod.* **52**, 1252 (1989).
26. H. Umezawa et al., *J. Antibiot. (Tokyo)* **39**, 170 (1986); M. Imoto et al., *Biochem. Int.* **15**, 98 (1987).
27. Y. Uehara et al., *ibid.* **41**, 831 (1988).
28. M. Cushman, *J. Med. Chem.* **34**, 798 (1991).
29. Y. Uehara et al., *Biochem. Biophys. Res. Commun.* **163**, 803 (1989).
30. M. Anafi et al., *Blood* **82**, 3524 (1993).
31. A. Gazit et al., unpublished results.
32. P. Miller et al., *Cancer Res.* **54**, 2724 (1994).
33. A. Gazit et al., unpublished results.
34. P. Yaish et al., *Science* **242**, 933 (1988).
35. A. Gazit et al., *J. Med. Chem.* **32**, 2344 (1989); A. Gazit et al., *ibid.* **34**, 1896 (1991); A. Gazit et al., *ibid.* **36**, 3556 (1993).
36. B. Margolis et al., *Cell* **57**, 1101 (1989).
37. R. Lyall et al., *J. Biol. Chem.* **264**, 14053 (1989); I. Posner et al., *FEBS Lett.* **257**, 287 (1989).
38. M. Bryckaert et al., *Exp. Cell. Res.* **199**, 255 (1991); A. Levitzki, C. Gilon, A. Gazit, U.S. Patent 5 196 446 (1993).
39. T. Shiraishi et al., *Chem. Pharm. Bull. (Tokyo)* **36**, 974 (1988); T. Shiraishi et al., *Cancer Res.* **49**, 2374 (1989); T. Shiraishi et al., *J. Cancer* **81**, 645 (1990).
40. T. Yoneda et al., *Cancer Res.* **51**, 4430 (1991).
41. S. Tanaka et al., *J. Antibiot. (Tokyo)* **47**, 294 (1994); T. Okabe et al., *ibid.*, p. 289.
42. M. Anafi et al., *J. Biol. Chem.* **267**, 4518 (1992); H. Chen et al., *J. Med. Chem.* **36**, 4094 (1993); G. Kaur et al., *Anti-Cancer Drugs* **5**, 213 (1994).
43. M. S. Smyth et al., *J. Med. Chem.* **36**, 3010 (1993).
44. A. J. Barker, European Patent Applications 0520722A1 (1992); D. W. Fry et al., *Science* **265**, 1093 (1994); H. J. Ward et al., *Biochem. Pharmacol.* **48**, 659 (1994); N. Osherov and A. Levitzki, *Eur. J. Biochem.* **225**, 1047 (1994). Recent experiments show that AG1478 inhibits cell growth in the low micromolar range, probably because it is competitive with ATP.
45. A. Gazit et al., unpublished results; F. Bohmer, unpublished results.
46. E. Buchdunger et al., *Proc. Natl. Acad. Sci. U.S.A.* **91**, 2334 (1994); U. Trinks et al., *J. Med. Chem.* **37**, 1015 (1994).
47. M. Kovalenko et al., *Cancer Res.* **54**, 6106 (1994).
48. J. F. Geissler et al., *J. Biol. Chem.* **265**, 22255 (1990).
49. N. Osherov et al., *ibid.* **268**, 11134 (1993).
50. N. Meydan et al., *Blood* **82** (suppl. 1), 360A (abstr.) (1993); N. Meydan et al., unpublished results.
51. G. Bilder et al., *Am. J. Physiol.* **260**, C721 (1991).
52. G. Golomb et al., *Am. Assoc. Pharmacol. Sci. Abs.*, in press; G. Golomb et al., unpublished results.
53. A. Novogrodsky et al., *Science* **264**, 1319 (1994).
54. P. Atadja, thesis, Hebrew University of Jerusalem (1991).
55. T. R. Burke et al., *Bioorg. Med. Chem. Lett.* **12**, 1711 (1992).
56. F. Rendu et al., *Biochem. Pharmacol.* **44**, 881 (1992); F. Rendu et al., *Blood Coagul. Fibrinolysis* **1**, 713 (1990); H. Salari et al., *FEBS Lett.* **263**, 104 (1990).
57. K. B. Reddy et al., *Cancer Res.* **52**, 3636 (1992).
58. R. L. Geahlen and J. L. McLaughlin, *Biochem. Biophys. Res. Commun.* **165**, 241 (1989); M. Cushman et al., *Bioorg. Med. Chem. Lett.* **2**, 15 (1991).
59. P. M. Traxler et al., *J. Med. Chem.* **34**, 2328 (1991).
60. A. Dvir et al., *J. Cell Biol.* **113**, 257 (1991); H. Ben-Bassat et al., *Exp. Dermatol.*, in press.
61. A. Gazit et al., unpublished results.
62. M. Ohmichi et al., *Biochemistry* **32**, 4650 (1993).
63. J. Spona, A. Gazit, A. Levitzki, in preparation; H. App et al., in preparation.
64. R. Saperstein et al., *Biochemistry* **28**, 5694 (1989).
65. T. Volberg et al., *EMBO J.* **11**, 1733 (1992); W. K. Agbotounou et al., *Mol. Pharmacol.* **45**, 922 (1994).
66. P. J. Gillespie et al., *Br. J. Cancer* **66**, 1122 (1993).
67. M. Anafi et al., *FEBS Lett.* **330**, 260 (1993).
68. H. B. Peng et al., *J. Cell Biol.* **120**, 197 (1993); L. P. Baker et al., *Neuron* **6**, 237 (1991).
69. C. Roifman et al., *J. Immunol.* **146**, 2965 (1991); S. Padeh et al., *J. Clin. Invest.* **87**, 1114 (1991).
70. J. B. Stanley et al., *J. Immunol.* **145**, 2180 (1991); E. Munoz et al., *Immunology* **77**, 43 (1992).
71. Z. Dong, C. A. O'Brien, I. J. Fidler, *J. Leukocyte Biol.* **53**, 53 (1993).
72. S. E. Lavens, P. T. Peachell, J. A. Warner, *Am. J. Respir. Cell. Mol. Biol.* **7**, 637 (1992); M. Krieger, V. van Tschamer, C. A. Dahinden, *Eur. J. Immunol.* **22**, 2907 (1992); A. Cohen-Dayag et al., *Int. Immunol.* **4**, 447 (1992); M. V. Sanguedolce et al., *J. Immunol.* **151**, 405 (1993).
73. R. M. Grossman et al., *Proc. Natl. Acad. Sci. U.S.A.* **86**, 6367 (1989).
74. M. Murakami et al., *Science* **260**, 1808 (1993).
75. J. F. Krane et al., *J. Invest. Dermatol.* **96**, 419 (1991).
76. B. Enssli et al., *Nature* **371**, 674 (1994).
77. J. E. Parillo, *N. Engl. J. Med.* **328**, 1471 (1993); C. R. H. Raetz et al., *FASEB J.* **5**, 2652 (1991).
78. I. Stefanova et al., *J. Biol. Chem.* **268**, 20725 (1993); Z. Dong, X. Qi, I. J. Fidler, *J. Exp. Med.* **177**, 1071 (1993); S. L. Weinstein, C. H. June, A. L. DeFranco, *J. Immunol.* **151**, 3829 (1993).
79. B. Beutler et al., *Annu. Rev. Biochem.* **57**, 505 (1988).
80. S. Okusawa et al., *J. Clin. Invest.* **81**, 1162 (1988); B. Everaerd et al., *Biochem. Biophys. Res. Com-*

- mun. 163, 378 (1989).
81. E. Munoz et al., *Eur. J. Immunol.* 22, 1391 (1993); M. Kohmo et al., *Biochem. J.* 267, 91 (1990); A. V. Hoffbard and R. G. Wickremasinghe, *Blood* 75, 88 (1990); G. R. Guy et al., *J. Biol. Chem.* 266, 14343 (1991).
 82. Z. Dong et al., *J. Immunol.* 151, 2717 (1993); T. Iwasaki et al., *FEBS Lett.* 298, 240 (1992).
 83. R. N. Maini et al., *Clin. Exp. Rheumatol.* 11 (suppl. 8), S173 (1993); F. M. Brennan, R. N. Maini, M. Feldmann, *J. Rheumatol.* 31, 293 (1992).
 84. C. Tsai et al., in preparation.
 85. M. Dukes et al., *J. Endocrinol.* 135, 239 (1992).
 86. S. R. Hubbard et al., *Nature* 372, 746 (1994).
 87. A. Levitzki, *Eur. J. Biochem.* 226, 1 (1994).
 88. The studies from the author's laboratory were supported by The Konover Cancer Fund of Hebrew University, by the Ministry of Health of Israel, and by SUGEN, Redwood City, CA. The authors also thank Martha Velorde of SUGEN for assistance in preparing the manuscript.

RESEARCH ARTICLE

Induction of Ectopic Eyes by Targeted Expression of the *eyeless* Gene in *Drosophila*

Georg Halder,* Patrick Callaerts,* Walter J. Gehring†

The *Drosophila* gene *eyeless* (*ey*) encodes a transcription factor with both a paired domain and a homeodomain. It is homologous to the mouse *Small eye* (*Pax-6*) gene and to the *Aniridia* gene in humans. These genes share extensive sequence identity, the position of three intron splice sites is conserved, and these genes are expressed similarly in the developing nervous system and in the eye during morphogenesis. Loss-of-function mutations in both the insect and in the mammalian genes have been shown to lead to a reduction or absence of eye structures, which suggests that *ey* functions in eye morphogenesis. By targeted expression of the *ey* complementary DNA in various imaginal disc primordia of *Drosophila*, ectopic eye structures were induced on the wings, the legs, and on the antennae. The ectopic eyes appeared morphologically normal and consisted of groups of fully differentiated ommatidia with a complete set of photoreceptor cells. These results support the proposition that *ey* is the master control gene for eye morphogenesis. Because homologous genes are present in vertebrates, ascidians, insects, cephalopods, and nemerteans, *ey* may function as a master control gene throughout the metazoa.

The *eyeless* (*ey*) mutation of *Drosophila* was first described in 1915 (1) on the basis of its characteristic phenotype, the partial or complete absence of the compound eyes. The *ey* alleles available today are recessive hypomorphs (weak alleles) and they lead to the reduction or complete absence of the compound eyes but do not affect the ocelli (simple eyes) on the head of the fly. Apparent null alleles that are lethal when homozygous have also been isolated (2), but they have been lost, and a detailed analysis of their phenotype is not available. Cloning and sequencing of the *ey* gene (3) have shown that it encodes a transcription factor that contains both a paired domain and a homeodomain. The *ey* gene is homologous to *Small eye* (*Sey* = *Pax-6*) in the mouse and to *Aniridia* in humans. The proteins encoded by these genes share 94 percent sequence identity in the paired domain, and 90 percent identity in the homeodomain and they con-

tain additional similarities in the flanking sequences. Furthermore, two out of three splice sites in the paired box and one out of two splice sites in the homeobox are conserved between the *Drosophila* and the mammalian genes, which indicates that these genes are orthologous.

Both the mouse and the *Drosophila* gene have similar expression patterns during development. In the mouse, the expression of *Sey* is observed in the spinal cord, in discrete regions of the brain, and in the developing eye. The *Sey* gene is expressed from the earliest stages until the end of eye morphogenesis: first, in the optic sulcus, and subsequently in the eye vesicle, in the lens, in the differentiating retina, and finally in the cornea (4). In *Drosophila*, *ey* is first expressed in the embryonic ventral nerve cord and in defined regions of the brain. Later in embryogenesis, *ey* is transcribed in the embryonic primordia of the eye as soon as these cells can be detected. In subsequent larval stages, it continues to be expressed in the developing eye imaginal discs. During the third larval stage, *ey* expression becomes largely restricted to the part of the eye disc that is

anterior to the morphogenetic furrow. This region consists of undifferentiated cells whereas posterior to the furrow the differentiating ommatidia are apparent (5). Because mutations in the mouse and *Drosophila* genes lead to a reduction or complete absence of all eye structures, and because these genes are similar in DNA sequence and in expression pattern even at the earliest stage of eye development, it has been suggested that *ey* and *Sey* may be the master control genes involved in eye morphogenesis (3). Furthermore, mutations in four other *Drosophila* genes with similar phenotypes (*eyes absent*, *sine oculis*, *eye gone*, and *eyelisch*) do not affect the expression pattern of *ey*, which indicates that *ey* acts upstream of these other genes (6). These results are consistent with its possible role as a gene that controls eye morphogenesis, even though it may have additional functions in the developing nervous system. The cloning of the homologous genes from ascidians, cephalopods, and nemerteans (ribbon worms) suggests that this gene may be present in all metazoa (3).

Master control genes that act as developmental switches can be detected on the basis of their mutant phenotypes. Thus, homeotic mutations have identified master control genes that specify the body plan along the antero-posterior axis. These genes, which are characterized by a homeobox, are clustered in the Antennapedia (*Antp*) and Bithorax Complexes in *Drosophila*, and in the Hox gene clusters of the mouse (7). Loss- and gain-of-function mutations in these genes lead to opposite homeotic transformations. For example, in *Antp*, recessive loss-of-function mutations are lethal at the embryonic or larval stage and lead to a transformation of the second thoracic segment (T2) toward the first thoracic segment (T2→T1). Dominant gain-of-function mutations lead to a transformation in the opposite direction, that is from the anterior head and T1 segments toward T2 (H,T1→T2) (8). These transformations can be explained by the combinatorial interaction of several homeotic genes in order to specify a given body segment. These genes have partially overlapping expression domains in several body segments and each segment is specified by a combination of homeobox genes, that is by a Hox code (9). By ubiquitous (ectopic) expression of *Antp* under the control of a heat-shock promoter, we have changed the body plan of *Drosophila* and induced the formation of middle legs in place of the antennae, and

Biozentrum, University of Basel, Klingelbergstrasse 70, CH-4056 Basel, Switzerland.

*The first two authors contributed equally to this work.
†To whom correspondence should be addressed.